ImmunoBiology Ltd. is pleased to announce the closing of its Series C funding round. The round was led by Inventages Venture Capital Investments Inc. Biosciences VTC also joined this funding round, along with all of ImmBio’s prior investors - Avlar BioVentures, Oxford Technology VCT and funds managed by Generics Asset Management and Yorkshire Fund Managers. Eight million Euro, with provision for follow on capital, has been raised.
Dr. Robert Schier, Partner of Inventages notes “ImmunoBiology’s technology leads to polyclonal immunity across a wide variety of viral and bacterial strains and is therefore very well suited for tackling some of the most challenging tasks in protecting people from life-threatening infectious disease. We believe that the highly experienced management team of the company will be able to transform the promises of its technology into safe and efficacious solutions to prevent and treat major diseases like Influenza, Tuberculosis and Hepatitis.”
Graham Clarke, CEO of ImmBio comments: “Having established proof of principle of the broad-based utility of the technology platform, this funding will enable ImmBio to progress its candidates into pre-clinical development”.
The technology platform (HspC™) is based on Heat Shock Protein Complexes (HspCs), which play the pivotal role of bridging between the innate and adaptive immunological response. The approach is expected to result in products with a broader, faster and safer profile compared with existing and new vaccines.
The work on Influenza includes studies of protection against major strain change, the current concern with avian ‘flu. ImmBio’s candidates have demonstrated protection, providing a robust basis for polyclonal immunity, required to address both gradual strain drift and strain shift. There is now widespread recognition of the risk posed from strain shift, potentially leading to global pandemic, due to lack of immunity.
|
